Why the study?
Does disease-targeted therapy improve survival in patients with Eisenmenger syndrome?
Does disease-targeted therapy improve survival in patients with Eisenmenger syndrome?
Disease-targeted therapy is associated with improved survival in Eisenmenger syndrome patients, who otherwise face alarmingly high 10-year mortality rates of 60-70%.
Answers are grounded in this paper and cite their sources.
DTT was associated with better survival in Eisenmenger syndrome; leaves open need for RCTs to confirm causality.
This study illustrates the alarmingly poor survival prospects of Eisenmenger patients by community-based data even in the current era with advanced DTT and in a country with a wealthy health system. Treatment naive ES patients had especially high mortality rates approaching 60-70% at 10 years of follow-up. Treatment with DTT was associated with better survival.
No takes yet. Share an insight, caveat, or question.
Diller et al. (2016) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: